

**Vaccination Coverage Statistics for Children in Northern Ireland:
Completed Primary Immunisations by 12 months**

| Quarter* | Year | No. in cohort | Dip3 | Tet3 | Pert3 | Pol (IPV)3 | Hib3 | HepB3 | MenC | PCV2 | PCV1 | Rota2 | MenB2 |
|-----------|------|---------------|-------|-------|-------|------------|-------|-------|-------|-------|-------|-------|-------|
| Jan-Mar | 2011 | 6066 | 97.4% | 97.4% | 97.4% | 97.4% | 97.4% | ~ | 97.3% | 97.5% | ~ | ~ | ~ |
| Apr-June | 2011 | 6089 | 97.3% | 97.3% | 97.3% | 97.3% | 97.3% | ~ | 97.2% | 97.4% | ~ | ~ | ~ |
| July-Sept | 2011 | 6515 | 97.4% | 97.4% | 97.4% | 97.4% | 97.4% | ~ | 97.4% | 97.5% | ~ | ~ | ~ |
| Oct-Dec | 2011 | 6557 | 97.5% | 97.5% | 97.5% | 97.5% | 97.5% | ~ | 97.3% | 97.6% | ~ | ~ | ~ |
| Jan-Mar | 2012 | 6145 | 97.2% | 97.2% | 97.2% | 97.2% | 97.2% | ~ | 97.0% | 97.1% | ~ | ~ | ~ |
| Apr-June | 2012 | 6022 | 97.3% | 97.3% | 97.3% | 97.3% | 97.3% | ~ | 97.3% | 97.5% | ~ | ~ | ~ |
| July-Sept | 2012 | 6563 | 97.3% | 97.3% | 97.3% | 97.3% | 97.3% | ~ | 97.3% | 97.4% | ~ | ~ | ~ |
| Oct-Dec | 2012 | 6253 | 97.4% | 97.4% | 97.4% | 97.4% | 97.4% | ~ | 97.3% | 97.4% | ~ | ~ | ~ |
| Jan-Mar | 2013 | 6195 | 97.4% | 97.4% | 97.4% | 97.4% | 97.4% | ~ | 97.4% | 97.4% | ~ | ~ | ~ |
| Apr-June | 2013 | 6165 | 97.7% | 97.7% | 97.7% | 97.7% | 97.7% | ~ | 97.7% | 97.7% | ~ | ~ | ~ |
| July-Sept | 2013 | 6394 | 97.4% | 97.4% | 97.4% | 97.4% | 97.4% | ~ | 96.8% | 97.4% | ~ | ~ | ~ |
| Oct-Dec | 2013 | 6382 | 97.2% | 97.2% | 97.2% | 97.2% | 97.2% | ~ | 94.1% | 97.2% | ~ | ~ | ~ |
| Jan-Mar | 2014 | 5784 | 96.7% | 96.7% | 96.7% | 96.7% | 96.7% | ~ | **n/a | 96.8% | ~ | ~ | ~ |
| Apr-June | 2014 | 5869 | 97.0% | 97.0% | 97.0% | 97.0% | 97.0% | ~ | **n/a | 96.8% | ~ | ~ | ~ |
| July-Sept | 2014 | 6431 | 97.6% | 97.6% | 97.6% | 97.6% | 97.6% | ~ | 98.6% | 97.6% | ~ | 94.3% | ~ |
| Oct-Dec | 2014 | 5923 | 97.9% | 97.9% | 97.9% | 97.9% | 97.9% | ~ | 98.6% | 97.8% | ~ | 94.9% | ~ |
| Jan-Mar | 2015 | 5854 | 97.5% | 97.5% | 97.5% | 97.5% | 97.5% | ~ | 98.5% | 97.5% | ~ | 94.8% | ~ |
| Apr-June | 2015 | 5920 | 97.4% | 97.4% | 97.4% | 97.4% | 97.4% | ~ | 98.4% | 97.3% | ~ | 94.9% | ~ |
| July-Sept | 2015 | 6439 | 97.2% | 97.2% | 97.2% | 97.2% | 97.2% | ~ | 98.2% | 97.1% | ~ | 94.1% | ~ |
| Oct-Dec | 2015 | 6104 | 97.3% | 97.3% | 97.3% | 97.3% | 97.3% | ~ | 98.2% | 97.4% | ~ | 94.3% | ~ |
| Jan-Mar | 2016 | 5712 | 97.1% | 97.1% | 97.1% | 97.1% | 97.1% | ~ | 98.4% | 97.1% | ~ | 94.8% | ~ |
| Apr-June | 2016 | 5891 | 96.7% | 96.7% | 96.7% | 96.7% | 96.7% | ~ | 97.8% | 96.7% | ~ | 94.2% | ~ |
| July-Sept | 2016 | 6469 | 97.1% | 97.1% | 97.1% | 97.1% | 97.1% | ~ | 97.8% | 97.1% | ~ | 94.5% | 96.0% |
| Oct-Dec | 2016 | 6206 | 96.6% | 96.6% | 96.6% | 96.6% | 96.6% | ~ | 97.3% | 96.7% | ~ | 94.3% | 95.7% |
| Jan-Mar | 2017 | 5752 | 96.9% | 96.9% | 96.9% | 96.9% | 96.9% | ~ | 90.4% | 97.0% | ~ | 95.1% | 96.5% |
| Apr-June | 2017 | 5981 | 96.7% | 96.7% | 96.7% | 96.7% | 96.7% | ~ | ~ | 96.8% | ~ | 94.8% | 96.3% |
| July-Sept | 2017 | 6312 | 96.6% | 96.6% | 96.6% | 96.6% | 96.6% | ~ | ~ | 96.8% | ~ | 94.5% | 96.3% |
| Oct-Dec | 2017 | 6057 | 96.3% | 96.3% | 96.3% | 96.3% | 96.3% | ~ | ~ | 96.5% | ~ | 93.9% | 96.2% |
| Jan-Mar | 2018 | 5649 | 95.5% | 95.5% | 95.5% | 95.5% | 95.5% | ~ | ~ | 95.8% | ~ | 93.7% | 95.4% |
| Apr-June | 2018 | 5587 | 95.1% | 95.1% | 95.1% | 95.1% | 95.1% | ~ | ~ | 95.4% | ~ | 93.6% | 95.2% |
| July-Sept | 2018 | 6073 | 94.5% | 94.5% | 94.5% | 94.5% | 94.5% | 94.5% | ~ | 94.9% | ~ | 92.3% | 94.7% |
| Oct-Dec | 2018 | 5844 | 94.0% | 94.0% | 94.0% | 94.0% | 94.0% | 94.0% | ~ | 94.4% | ~ | 92.2% | 94.1% |
| Jan-Mar | 2019 | 5364 | 94.2% | 94.2% | 94.2% | 94.2% | 94.2% | 94.2% | ~ | 94.5% | ~ | 91.9% | 94.1% |
| Apr-June | 2019 | 5728 | 93.8% | 93.8% | 93.8% | 93.8% | 93.8% | 93.8% | ~ | 94.1% | ~ | 91.6% | 93.9% |
| July-Sept | 2019 | 6007 | 94.0% | 94.0% | 94.0% | 94.0% | 94.0% | 94.0% | ~ | 94.4% | ~ | 91.3% | 94.2% |
| Oct-Dec | 2019 | 5694 | 95.0% | 95.0% | 95.0% | 95.0% | 95.0% | 95.0% | ~ | 95.3% | ~ | 92.1% | 95.0% |
| Jan-Mar | 2020 | 5411 | 94.8% | 94.8% | 94.8% | 94.8% | 94.8% | 94.8% | ~ | 95.3% | ~ | 92.6% | 95.0% |
| Apr-June | 2020 | 5505 | 94.9% | 94.9% | 94.9% | 94.9% | 94.9% | 94.9% | ~ | 95.4% | ~ | 93.0% | 95.1% |
| July-Sept | 2020 | 5954 | 94.5% | 94.5% | 94.5% | 94.5% | 94.5% | 94.5% | ~ | 94.9% | ~ | 92.5% | 94.6% |
| Oct-Dec | 2020 | 5591 | 93.7% | 93.7% | 93.7% | 93.7% | 93.7% | 93.7% | ~ | 93.5% | ~ | 91.7% | 94.0% |
| Jan-Mar | 2021 | 5344 | 94.3% | 94.3% | 94.3% | 94.3% | 94.3% | 94.3% | ~ | ~ | 96.0% | 92.3% | 94.4% |
| Apr-June | 2021 | 5185 | 93.6% | 93.6% | 93.6% | 93.6% | 93.6% | 93.6% | ~ | ~ | 95.7% | 91.6% | 93.9% |
| July-Sept | 2021 | 5647 | 93.3% | 93.3% | 93.3% | 93.3% | 93.3% | 93.3% | ~ | ~ | 95.0% | 90.2% | 93.6% |
| Oct-Dec | 2021 | 5352 | 93.7% | 93.7% | 93.7% | 93.7% | 93.7% | 93.7% | ~ | ~ | 95.3% | 91.1% | 94.0% |

* children were 12 months old during the quarter

** accurate Men C coverage at 12 months not available (n/a) due to a software change

Dip3 = Diphtheria (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017

Tet3 = Tetanus (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017

Pert3 = Pertussis (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017

Pol (IPV)3 = Polio (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017

Hib3 = *Haemophilus Influenzae* type b (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017

HepB3 = Hepatitis B (DTaP/IPV/Hib/HepB3 vaccine) (3 doses) (introduced in August 2017)

MenC = Meningococcal serogroup C conjugate vaccine was removed from the routine immunisation schedule from 1st July 2016 and children born Jan to Mar 2016 but presenting for their 12 week immunisation late (after 1 July) may not have been offered the vaccine, resulting in decrease in coverage in Mar 2017
~ Meningococcal serogroup C conjugate vaccine reporting ceased in April 2017

PCV2 = Pneumococcal conjugate vaccine (2 doses) (introduced Sept 2006)

PCV1= Changes to PCV schedule: All infants born on or after 1 January 2020 offered a single dose of PCV13 followed by a PCV13 booster at one year old (on or after the first birthday). This is referred to as a 1 + 1 PCV schedule. This 1 + 1 schedule will replace the previous schedule of 2 + 1 (at 8 and 16 weeks, and a booster dose given at one year old (on or after the first birthday)). Jan-Mar 2021 is the first quarter where only PCV1 coverage at 12 months has been evaluated

Rota2 = Rotavirus vaccine (2 doses given before 24 weeks of age) (introduced July 2013)

MenB2 = Meningococcal serogroup B vaccine (2 doses) (introduced Sept 2015)

**Vaccination Coverage Statistics for Children in BHSCT:
Completed Primary Immunisations by 12 months**

| Quarter* | Year | No. in cohort | Dip3 | Tet3 | Pert3 | Pol (IPV)3 | Hib3 | HepB3 | MenC | PCV2 | PCV1 | Rota2 | MenB2 |
|-----------|------|---------------|-------|-------|-------|------------|-------|-------|-------|-------|-------|-------|-------|
| Jan-Mar | 2011 | 1076 | 95.6% | 95.6% | 95.6% | 95.6% | 95.6% | ~ | 95.4% | 95.5% | ~ | ~ | ~ |
| Apr-June | 2011 | 1149 | 95.3% | 95.3% | 95.3% | 95.3% | 95.3% | ~ | 95.0% | 95.4% | ~ | ~ | ~ |
| July-Sept | 2011 | 1223 | 95.0% | 95.0% | 95.0% | 95.0% | 95.0% | ~ | 95.1% | 95.3% | ~ | ~ | ~ |
| Oct-Dec | 2011 | 1317 | 94.8% | 94.8% | 94.8% | 94.8% | 94.8% | ~ | 94.5% | 95.3% | ~ | ~ | ~ |
| Jan-Mar | 2012 | 1157 | 95.1% | 95.1% | 95.1% | 95.1% | 95.1% | ~ | 94.7% | 95.3% | ~ | ~ | ~ |
| Apr-June | 2012 | 1099 | 95.5% | 95.5% | 95.5% | 95.5% | 95.5% | ~ | 95.2% | 95.4% | ~ | ~ | ~ |
| July-Sept | 2012 | 1270 | 96.0% | 96.0% | 96.0% | 96.0% | 96.0% | ~ | 96.1% | 96.1% | ~ | ~ | ~ |
| Oct-Dec | 2012 | 1216 | 95.2% | 95.2% | 95.2% | 95.2% | 95.2% | ~ | 95.0% | 95.2% | ~ | ~ | ~ |
| Jan-Mar | 2013 | 1231 | 95.0% | 95.0% | 95.0% | 95.0% | 95.0% | ~ | 95.2% | 95.2% | ~ | ~ | ~ |
| Apr-June | 2013 | 1169 | 95.2% | 95.2% | 95.2% | 95.2% | 95.2% | ~ | 95.0% | 95.5% | ~ | ~ | ~ |
| July-Sept | 2013 | 1213 | 93.7% | 93.7% | 93.7% | 93.7% | 93.7% | ~ | 93.1% | 94.1% | ~ | ~ | ~ |
| Oct-Dec | 2013 | 1234 | 94.7% | 94.7% | 94.7% | 94.7% | 94.7% | ~ | 90.6% | 94.7% | ~ | ~ | ~ |
| Jan-Mar | 2014 | 1117 | 93.4% | 93.4% | 93.4% | 93.4% | 93.4% | ~ | **n/a | 93.6% | ~ | ~ | ~ |
| Apr-June | 2014 | 1120 | 94.1% | 94.1% | 94.1% | 94.1% | 94.1% | ~ | **n/a | 93.6% | ~ | ~ | ~ |
| July-Sept | 2014 | 1263 | 95.9% | 95.9% | 95.9% | 95.9% | 95.9% | ~ | 97.7% | 96.0% | ~ | 93.0% | ~ |
| Oct-Dec | 2014 | 1131 | 95.2% | 95.2% | 95.2% | 95.2% | 95.2% | ~ | 97.1% | 95.2% | ~ | 92.0% | ~ |
| Jan-Mar | 2015 | 1101 | 95.8% | 95.8% | 95.8% | 95.8% | 95.8% | ~ | 97.8% | 95.8% | ~ | 93.7% | ~ |
| Apr-June | 2015 | 1149 | 95.5% | 95.5% | 95.5% | 95.5% | 95.5% | ~ | 97.6% | 95.3% | ~ | 93.3% | ~ |
| July-Sept | 2015 | 1198 | 94.4% | 94.4% | 94.4% | 94.4% | 94.4% | ~ | 97.4% | 94.2% | ~ | 92.7% | ~ |
| Oct-Dec | 2015 | 1151 | 94.9% | 94.9% | 94.9% | 94.9% | 94.9% | ~ | 96.5% | 95.0% | ~ | 93.0% | ~ |
| Jan-Mar | 2016 | 1113 | 94.6% | 94.6% | 94.6% | 94.6% | 94.6% | ~ | 97.3% | 95.1% | ~ | 94.0% | ~ |
| Apr-June | 2016 | 1108 | 94.0% | 94.0% | 94.0% | 94.0% | 94.0% | ~ | 95.4% | 94.0% | ~ | 92.0% | ~ |
| July-Sept | 2016 | 1157 | 93.9% | 93.9% | 93.9% | 93.9% | 93.9% | ~ | 95.7% | 94.0% | ~ | 92.0% | 92.6% |
| Oct-Dec | 2016 | 1140 | 93.5% | 93.5% | 93.5% | 93.5% | 93.5% | ~ | 95.5% | 93.5% | ~ | 92.5% | 92.7% |
| Jan-Mar | 2017 | 1062 | 94.3% | 94.3% | 94.3% | 94.3% | 94.3% | ~ | 87.8% | 94.5% | ~ | 93.9% | 94.3% |
| Apr-June | 2017 | 1103 | 93.0% | 93.0% | 93.0% | 93.0% | 93.0% | ~ | ~ | 93.3% | ~ | 90.6% | 92.7% |
| July-Sept | 2017 | 1187 | 94.3% | 94.3% | 94.3% | 94.3% | 94.3% | ~ | ~ | 94.3% | ~ | 92.8% | 93.9% |
| Oct-Dec | 2017 | 1196 | 94.1% | 94.1% | 94.1% | 94.1% | 94.1% | ~ | ~ | 94.1% | ~ | 92.6% | 93.8% |
| Jan-Mar | 2018 | 1057 | 92.4% | 92.4% | 92.4% | 92.4% | 92.4% | ~ | ~ | 92.7% | ~ | 93.3% | 92.2% |
| Apr-June | 2018 | 990 | 89.4% | 89.4% | 89.4% | 89.4% | 89.4% | ~ | ~ | 89.8% | ~ | 91.0% | 89.6% |
| July-Sept | 2018 | 1083 | 89.4% | 89.4% | 89.4% | 89.4% | 89.4% | 89.4% | ~ | 90.1% | ~ | 89.3% | 89.6% |
| Oct-Dec | 2018 | 1087 | 86.6% | 86.6% | 86.6% | 86.6% | 86.6% | 86.6% | ~ | 87.3% | ~ | 86.3% | 86.7% |
| Jan-Mar | 2019 | 1009 | 88.7% | 88.7% | 88.7% | 88.7% | 88.7% | ~ | ~ | 89.3% | ~ | 88.4% | 88.6% |
| Apr-June | 2019 | 1056 | 86.5% | 86.5% | 86.5% | 86.5% | 86.5% | 86.5% | ~ | 87.2% | ~ | 85.7% | 86.9% |
| July-Sept | 2019 | 1173 | 87.7% | 87.7% | 87.7% | 87.7% | 87.7% | 87.7% | ~ | 88.7% | ~ | 86.7% | 88.5% |
| Oct-Dec | 2019 | 1066 | 89.4% | 89.4% | 89.4% | 89.4% | 89.4% | 89.4% | ~ | 90.1% | ~ | 88.5% | 90.0% |
| Jan-Mar | 2020 | 989 | 90.0% | 90.0% | 90.0% | 90.0% | 90.0% | 90.0% | ~ | 90.4% | ~ | 89.9% | 90.4% |
| Apr-June | 2020 | 1052 | 90.5% | 90.5% | 90.5% | 90.5% | 90.5% | 90.5% | ~ | 91.1% | ~ | 90.4% | 90.8% |
| July-Sept | 2020 | 1138 | 89.9% | 89.9% | 89.9% | 89.9% | 89.9% | 89.9% | ~ | 89.9% | ~ | 89.0% | 89.6% |
| Oct-Dec | 2020 | 1061 | 87.7% | 87.7% | 87.7% | 87.7% | 87.7% | 87.7% | ~ | 87.8% | ~ | 86.6% | 88.1% |
| Jan-Mar | 2021 | 987 | 89.9% | 89.9% | 89.9% | 89.9% | 89.9% | 89.9% | ~ | ~ | 92.3% | 88.8% | 90.0% |
| Apr-June | 2021 | 985 | 88.9% | 88.9% | 88.9% | 88.9% | 88.9% | 88.9% | ~ | ~ | ~ | 94.3% | 89.5% |
| Jul-Sept | 2021 | 1044 | 87.9% | 87.9% | 87.9% | 87.9% | 87.9% | 87.9% | ~ | ~ | 90.4% | 85.3% | 88.3% |
| Oct-Dec | 2021 | 998 | 87.2% | 87.2% | 87.2% | 87.2% | 87.2% | 87.2% | ~ | ~ | 91.3% | 85.6% | 88.1% |

* children were 12 months old during the quarter

** accurate Men C coverage at 12 months not available (n/a) due to a software change

Dip3 = Diphtheria (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017

Tet3 = Tetanus (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017

Pert3 = Pertussis (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017

Pol (IPV)3 = Polio (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017

Hib3 = *Haemophilus Influenzae* type b (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017

HepB3 = Hepatitis B (DTaP/IPV/Hib/HepB3 vaccine) (3 doses) (introduced in August 2017)

MenC = Meningococcal serogroup C conjugate vaccine was removed from the routine immunisation schedule from 1st July 2016 and children born Jan to Mar 2016

but presenting for their 12 week immunisation late (after 1 July) may not have been offered the vaccine, resulting in decrease in coverage in Mar 2017

~ Meningococcal serogroup C conjugate vaccine reporting ceased in April 2017

PCV2 = Pneumococcal conjugate vaccine (2 doses) (introduced Sept 2006)

PCV1= Changes to PCV schedule: All infants born on or after 1 January 2020 offered a single dose of PCV13 followed by a PCV13 booster at one year old (on or after the first birthday).

This is referred to as a 1 + 1 PCV schedule. This 1 + 1 schedule will replace the previous schedule of 2 + 1 (at 8 and 16 weeks, and a booster dose given at one year old (on or after the first birthday)).

Jan-Mar 2021 is the first quarter where only PCV1 coverage at 12 months has been evaluated

Rota2 = Rotavirus vaccine (2 doses given before 24 weeks of age) (introduced July 2013)

MenB2 = Meningococcal serogroup B vaccine (2 doses) (introduced Sept 2015)

**Vaccination Coverage Statistics for Children in SEHSCT:
Completed Primary Immunisations by 12 months**

| Quarter* | Year | No. in cohort | Dip3 | Tet3 | Pert3 | Pol (IPV)3 | Hib3 | HepB3 | MenC | PCV2 | PCV1 | Rota2 | MenB2 |
|-----------|------|---------------|-------|-------|-------|------------|-------|-------|-------|-------|-------|-------|-------|
| Jan-Mar | 2011 | 1088 | 97.0% | 97.0% | 97.0% | 97.0% | 97.0% | ~ | 97.0% | 97.2% | ~ | ~ | ~ |
| Apr-June | 2011 | 1102 | 97.2% | 97.2% | 97.2% | 97.2% | 97.2% | ~ | 96.9% | 97.3% | ~ | ~ | ~ |
| July-Sept | 2011 | 1175 | 97.7% | 97.7% | 97.7% | 97.7% | 97.7% | ~ | 97.7% | 98.0% | ~ | ~ | ~ |
| Oct-Dec | 2011 | 1181 | 97.5% | 97.5% | 97.5% | 97.5% | 97.5% | ~ | 97.3% | 97.5% | ~ | ~ | ~ |
| Jan-Mar | 2012 | 1077 | 96.8% | 96.8% | 96.8% | 96.8% | 96.8% | ~ | 96.8% | 96.8% | ~ | ~ | ~ |
| Apr-June | 2012 | 1114 | 97.8% | 97.8% | 97.8% | 97.8% | 97.8% | ~ | 97.8% | 97.8% | ~ | ~ | ~ |
| July-Sept | 2012 | 1235 | 96.4% | 96.4% | 96.4% | 96.4% | 96.4% | ~ | 96.3% | 96.3% | ~ | ~ | ~ |
| Oct-Dec | 2012 | 1148 | 97.1% | 97.1% | 97.1% | 97.1% | 97.1% | ~ | 97.1% | 97.5% | ~ | ~ | ~ |
| Jan-Mar | 2013 | 1153 | 97.3% | 97.3% | 97.3% | 97.3% | 97.3% | ~ | 97.4% | 97.7% | ~ | ~ | ~ |
| Apr-June | 2013 | 1106 | 98.6% | 98.6% | 98.6% | 98.6% | 98.6% | ~ | 98.6% | 98.6% | ~ | ~ | ~ |
| July-Sept | 2013 | 1106 | 97.4% | 97.4% | 97.4% | 97.4% | 97.4% | ~ | 97.0% | 97.5% | ~ | ~ | ~ |
| Oct-Dec | 2013 | 1148 | 97.4% | 97.4% | 97.4% | 97.4% | 97.4% | ~ | 95.0% | 97.6% | ~ | ~ | ~ |
| Jan-Mar | 2014 | 1074 | 96.3% | 96.3% | 96.3% | 96.3% | 96.3% | ~ | **n/a | 96.5% | ~ | ~ | ~ |
| Apr-June | 2014 | 1076 | 97.8% | 97.8% | 97.8% | 97.8% | 97.8% | ~ | **n/a | 97.9% | ~ | ~ | ~ |
| July-Sept | 2014 | 1155 | 97.9% | 97.9% | 97.9% | 97.9% | 97.9% | ~ | 99.0% | 97.7% | ~ | 93.1% | ~ |
| Oct-Dec | 2014 | 1020 | 97.6% | 97.6% | 97.6% | 97.6% | 97.6% | ~ | 98.6% | 97.7% | ~ | 95.4% | ~ |
| Jan-Mar | 2015 | 1054 | 97.2% | 97.2% | 97.2% | 97.2% | 97.2% | ~ | 98.3% | 97.3% | ~ | 94.2% | ~ |
| Apr-June | 2015 | 1050 | 97.6% | 97.6% | 97.6% | 97.6% | 97.6% | ~ | 98.5% | 97.5% | ~ | 95.0% | ~ |
| July-Sept | 2015 | 1188 | 97.1% | 97.1% | 97.1% | 97.1% | 97.1% | ~ | 97.9% | 97.3% | ~ | 94.5% | ~ |
| Oct-Dec | 2015 | 1054 | 97.2% | 97.2% | 97.2% | 97.2% | 97.2% | ~ | 98.1% | 97.2% | ~ | 93.7% | ~ |
| Jan-Mar | 2016 | 1011 | 97.6% | 97.6% | 97.6% | 97.6% | 97.6% | ~ | 98.2% | 97.5% | ~ | 94.9% | ~ |
| Apr-June | 2016 | 1073 | 96.1% | 96.1% | 96.1% | 96.1% | 96.1% | ~ | 97.9% | 96.3% | ~ | 94.7% | ~ |
| July-Sept | 2016 | 1209 | 97.5% | 97.5% | 97.5% | 97.5% | 97.5% | ~ | 97.9% | 97.4% | ~ | 95.1% | 96.8% |
| Oct-Dec | 2016 | 1093 | 97.3% | 97.3% | 97.3% | 97.3% | 97.3% | ~ | 97.8% | 97.3% | ~ | 95.2% | 96.3% |
| Jan-Mar | 2017 | 1046 | 97.3% | 97.3% | 97.3% | 97.3% | 97.3% | ~ | 90.1% | 97.4% | ~ | 94.0% | 96.6% |
| Apr-June | 2017 | 1094 | 96.3% | 96.3% | 96.3% | 96.3% | 96.3% | ~ | ~ | 96.6% | ~ | 94.4% | 96.2% |
| July-Sept | 2017 | 1127 | 96.6% | 96.6% | 96.6% | 96.6% | 96.6% | ~ | ~ | 96.7% | ~ | 94.9% | 96.4% |
| Oct-Dec | 2017 | 1043 | 96.4% | 96.4% | 96.4% | 96.4% | 96.4% | ~ | ~ | 96.4% | ~ | 94.7% | 96.2% |
| Jan-Mar | 2018 | 1022 | 95.7% | 95.7% | 95.7% | 95.7% | 95.7% | ~ | ~ | 96.2% | ~ | 93.9% | 96.0% |
| Apr-June | 2018 | 963 | 95.5% | 95.5% | 95.5% | 95.5% | 95.5% | ~ | ~ | 95.8% | ~ | 93.1% | 95.5% |
| July-Sept | 2018 | 1026 | 95.1% | 95.1% | 95.1% | 95.1% | 95.1% | 95.1% | ~ | 95.5% | ~ | 91.9% | 95.3% |
| Oct-Dec | 2018 | 1031 | 95.0% | 95.0% | 95.0% | 95.0% | 95.0% | 95.0% | ~ | 95.1% | ~ | 92.0% | 95.0% |
| Jan-Mar | 2019 | 968 | 95.1% | 95.1% | 95.1% | 95.1% | 95.1% | 95.1% | ~ | 95.5% | ~ | 91.3% | 95.0% |
| Apr-June | 2019 | 1017 | 95.6% | 95.6% | 95.6% | 95.6% | 95.6% | 95.6% | ~ | 95.8% | ~ | 92.7% | 95.5% |
| July-Sept | 2019 | 1078 | 94.2% | 94.2% | 94.2% | 94.2% | 94.2% | 94.2% | ~ | 94.6% | ~ | 91.5% | 94.5% |
| Oct-Dec | 2019 | 1020 | 96.6% | 96.6% | 96.6% | 96.6% | 96.6% | 96.6% | ~ | 96.7% | ~ | 93.0% | 96.2% |
| Jan-Mar | 2020 | 946 | 94.8% | 94.8% | 94.8% | 94.8% | 94.8% | 94.8% | ~ | 94.7% | ~ | 92.4% | 94.6% |
| Apr-June | 2020 | 998 | 94.0% | 94.0% | 94.0% | 94.0% | 94.0% | 94.0% | ~ | 94.3% | ~ | 92.7% | 94.1% |
| July-Sept | 2020 | 1044 | 94.3% | 94.3% | 94.3% | 94.3% | 94.3% | 94.3% | ~ | 95.0% | ~ | 92.7% | 94.9% |
| Oct-Dec | 2020 | 940 | 91.8% | 91.8% | 91.8% | 91.8% | 91.8% | 91.8% | ~ | 91.6% | ~ | 90.2% | 92.6% |
| Jan-Mar | 2021 | 950 | 93.7% | 93.7% | 93.7% | 93.7% | 93.7% | 93.7% | ~ | ~ | 96.6% | 92.7% | 94.1% |
| Apr-June | 2021 | 883 | 91.3% | 91.3% | 91.3% | 91.3% | 91.3% | 91.3% | ~ | ~ | 93.7% | 88.8% | 91.6% |
| July-Sept | 2021 | 1014 | 91.4% | 91.4% | 91.4% | 91.4% | 91.4% | 91.4% | ~ | ~ | 93.4% | 88.2% | 91.0% |
| Oct-Dec | 2021 | 903 | 92.2% | 92.2% | 92.2% | 92.2% | 92.2% | 92.2% | ~ | ~ | 93.7% | 89.9% | 92.4% |

* children were 12 months old during the quarter

** accurate Men C coverage at 12 months not available (n/a) due to a software change

Dip3 = Diphtheria (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017

Tet3 = Tetanus (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017

Pert3 = Pertussis (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017

Pol (IPV)3 = Polio (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017

Hib3 = *Haemophilus Influenzae* type b (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017

HepB3 = Hepatitis B (DTaP/IPV/Hib/HepB3 vaccine) (3 doses) (introduced in August 2017)

MenC = Meningococcal serogroup C conjugate vaccine was removed from the routine immunisation schedule from 1st July 2016 and children born Jan to Mar 2016 but presenting for their 12 week immunisation late (after 1 July) may not have been offered the vaccine, resulting in decrease in coverage in Mar 2017
~ Meningococcal serogroup C conjugate vaccine reporting ceased in April 2017

PCV2 = Pneumococcal conjugate vaccine (2 doses) (introduced Sept 2006)

PCV1= Changes to PCV schedule: All infants born on or after 1 January 2020 offered a single dose of PCV13 followed by a PCV13 booster at one year old (on or a This is referred to as a 1 + 1 PCV schedule. This 1 + 1 schedule will replace the previous schedule of 2 + 1 (at 8 and 16 weeks, and a booster dose given at

**Vaccination Coverage Statistics for Children in NHSCT:
Completed Primary Immunisations by 12 months**

| Quarter* | Year | No. in cohort | Dip3 | Tet3 | Pert3 | Pol (IPV)3 | Hib3 | HepB3 | MenC | PCV2 | PCV1 | Rota2 | MenB2 |
|-----------|------|---------------|-------|-------|-------|------------|-------|-------|-------|-------|-------|-------|-------|
| Jan-Mar | 2011 | 1442 | 97.9% | 97.9% | 97.9% | 97.9% | 97.9% | ~ | 97.7% | 97.9% | ~ | ~ | ~ |
| Apr-June | 2011 | 1466 | 97.9% | 97.9% | 97.9% | 97.9% | 97.9% | ~ | 97.9% | 98.0% | ~ | ~ | ~ |
| July-Sept | 2011 | 1562 | 97.3% | 97.3% | 97.3% | 97.3% | 97.3% | ~ | 97.3% | 97.2% | ~ | ~ | ~ |
| Oct-Dec | 2011 | 1554 | 98.1% | 98.1% | 98.1% | 98.1% | 98.1% | ~ | 97.9% | 98.3% | ~ | ~ | ~ |
| Jan-Mar | 2012 | 1483 | 97.6% | 97.6% | 97.6% | 97.6% | 97.6% | ~ | 97.4% | 97.4% | ~ | ~ | ~ |
| Apr-June | 2012 | 1476 | 96.8% | 96.8% | 96.8% | 96.8% | 96.8% | ~ | 96.7% | 97.0% | ~ | ~ | ~ |
| July-Sept | 2012 | 1535 | 97.5% | 97.5% | 97.5% | 97.5% | 97.5% | ~ | 97.1% | 97.5% | ~ | ~ | ~ |
| Oct-Dec | 2012 | 1458 | 97.9% | 97.9% | 97.9% | 97.9% | 97.9% | ~ | 97.9% | 98.0% | ~ | ~ | ~ |
| Jan-Mar | 2013 | 1446 | 97.6% | 97.6% | 97.6% | 97.6% | 97.6% | ~ | 97.4% | 97.5% | ~ | ~ | ~ |
| Apr-June | 2013 | 1448 | 97.3% | 97.3% | 97.3% | 97.3% | 97.3% | ~ | 97.2% | 97.2% | ~ | ~ | ~ |
| July-Sept | 2013 | 1536 | 98.1% | 98.1% | 98.1% | 98.1% | 98.1% | ~ | 97.1% | 97.9% | ~ | ~ | ~ |
| Oct-Dec | 2013 | 1521 | 97.6% | 97.6% | 97.6% | 97.6% | 97.6% | ~ | 94.3% | 97.6% | ~ | ~ | ~ |
| Jan-Mar | 2014 | 1395 | 97.6% | 97.6% | 97.6% | 97.6% | 97.6% | ~ | **n/a | 97.6% | ~ | ~ | ~ |
| Apr-June | 2014 | 1432 | 96.2% | 96.2% | 96.2% | 96.2% | 96.2% | ~ | **n/a | 96.2% | ~ | ~ | ~ |
| July-Sept | 2014 | 1538 | 97.7% | 97.7% | 97.7% | 97.7% | 97.7% | ~ | 98.8% | 97.6% | ~ | 95.7% | ~ |
| Oct-Dec | 2014 | 1432 | 98.5% | 98.5% | 98.5% | 98.5% | 98.5% | ~ | 98.8% | 98.3% | ~ | 94.8% | ~ |
| Jan-Mar | 2015 | 1416 | 97.7% | 97.7% | 97.7% | 97.7% | 97.7% | ~ | 98.8% | 97.7% | ~ | 95.1% | ~ |
| Apr-June | 2015 | 1388 | 97.9% | 97.9% | 97.9% | 97.9% | 97.9% | ~ | 98.8% | 98.0% | ~ | 95.9% | ~ |
| July-Sept | 2015 | 1547 | 97.6% | 97.6% | 97.6% | 97.6% | 97.6% | ~ | 98.1% | 97.4% | ~ | 94.1% | ~ |
| Oct-Dec | 2015 | 1504 | 98.4% | 98.4% | 98.4% | 98.4% | 98.4% | ~ | 98.9% | 98.3% | ~ | 94.9% | ~ |
| Jan-Mar | 2016 | 1374 | 97.5% | 97.5% | 97.5% | 97.5% | 97.5% | ~ | 98.4% | 97.5% | ~ | 95.0% | ~ |
| Apr-June | 2016 | 1425 | 97.9% | 97.9% | 97.9% | 97.9% | 97.9% | ~ | 98.9% | 98.0% | ~ | 95.1% | ~ |
| July-Sept | 2016 | 1523 | 98.2% | 98.2% | 98.2% | 98.2% | 98.2% | ~ | 98.8% | 98.2% | ~ | 95.3% | 97.2% |
| Oct-Dec | 2016 | 1486 | 97.2% | 97.2% | 97.2% | 97.2% | 97.2% | ~ | 97.7% | 97.2% | ~ | 94.7% | 95.9% |
| Jan-Mar | 2017 | 1323 | 97.6% | 97.6% | 97.6% | 97.6% | 97.6% | ~ | 90.6% | 97.5% | ~ | 96.1% | 97.0% |
| Apr-June | 2017 | 1426 | 97.4% | 97.4% | 97.4% | 97.4% | 97.4% | ~ | ~ | 97.4% | ~ | 96.1% | 97.0% |
| July-Sept | 2017 | 1488 | 96.8% | 96.8% | 96.8% | 96.8% | 96.8% | ~ | ~ | 97.1% | ~ | 95.4% | 96.6% |
| Oct-Dec | 2017 | 1472 | 96.9% | 96.9% | 96.9% | 96.9% | 96.9% | ~ | ~ | 97.1% | ~ | 95.0% | 96.7% |
| Jan-Mar | 2018 | 1364 | 96.0% | 96.0% | 96.0% | 96.0% | 96.0% | ~ | ~ | 96.2% | ~ | 93.8% | 95.8% |
| Apr-June | 2018 | 1326 | 95.6% | 95.6% | 95.6% | 95.6% | 95.6% | ~ | ~ | 96.3% | ~ | 93.7% | 96.2% |
| July-Sept | 2018 | 1496 | 95.3% | 95.3% | 95.3% | 95.3% | 95.3% | 95.3% | ~ | 95.7% | ~ | 92.6% | 95.5% |
| Oct-Dec | 2018 | 1400 | 96.3% | 96.3% | 96.3% | 96.3% | 96.3% | 96.3% | ~ | 96.6% | ~ | 94.4% | 96.4% |
| Jan-Mar | 2019 | 1228 | 95.4% | 95.4% | 95.4% | 95.4% | 95.4% | 95.4% | ~ | 95.4% | ~ | 92.8% | 95.2% |
| Apr-June | 2019 | 1361 | 95.3% | 95.3% | 95.3% | 95.3% | 95.3% | 95.3% | ~ | 95.5% | ~ | 94.1% | 95.3% |
| July-Sept | 2019 | 1381 | 95.7% | 95.7% | 95.7% | 95.7% | 95.7% | 95.7% | ~ | 95.9% | ~ | 93.3% | 95.5% |
| Oct-Dec | 2019 | 1340 | 96.6% | 96.6% | 96.6% | 96.6% | 96.6% | 96.6% | ~ | 97.1% | ~ | 93.8% | 96.9% |
| Jan-Mar | 2020 | 1302 | 96.5% | 96.5% | 96.5% | 96.5% | 96.5% | 96.5% | ~ | 96.7% | ~ | 94.0% | 96.3% |
| Apr-June | 2020 | 1302 | 97.2% | 97.2% | 97.2% | 97.2% | 97.2% | 97.2% | ~ | 97.6% | ~ | 95.7% | 97.5% |
| July-Sept | 2020 | 1418 | 95.8% | 95.8% | 95.8% | 95.8% | 95.8% | 95.8% | ~ | 96.1% | ~ | 94.1% | 96.0% |
| Oct-Dec | 2020 | 1359 | 95.6% | 95.6% | 95.6% | 95.6% | 95.6% | 95.6% | ~ | 95.5% | ~ | 94.6% | 95.7% |
| Jan-Mar | 2021 | 1257 | 96.2% | 96.2% | 96.2% | 96.2% | 96.2% | 96.2% | ~ | ~ | 96.7% | 92.9% | 96.1% |
| Apr-June | 2021 | 1283 | 95.6% | 95.6% | 95.6% | 95.6% | 95.6% | 95.6% | ~ | ~ | 96.8% | 93.4% | 95.8% |
| July-Sept | 2021 | 1382 | 95.6% | 95.6% | 95.6% | 95.6% | 95.6% | 95.6% | ~ | ~ | 97.0% | 92.8% | 95.9% |
| Oct-Dec | 2021 | 1268 | 97.8% | 97.8% | 97.8% | 97.8% | 97.8% | 97.8% | ~ | ~ | 98.3% | 94.9% | 97.8% |

* children were 12 months old during the quarter

** accurate Men C coverage at 12 months not available (n/a) due to a software change

Dip3 = Diphtheria (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017

Tet3 = Tetanus (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017

Pert3 = Pertussis (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017

Pol (IPV)3 = Polio (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017

Hib3 = *Haemophilus Influenzae* type b (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017

HepB3 = Hepatitis B (DTaP/IPV/Hib/HepB3 vaccine) (3 doses) (introduced in August 2017)

MenC = Meningococcal serogroup C conjugate vaccine was removed from the routine immunisation schedule from 1st July 2016 and children born Jan to Mar 2016 but presenting for their 12 week immunisation late (after 1 July) may not have been offered the vaccine, resulting in decrease in coverage in Mar 2017
~ Meningococcal serogroup C conjugate vaccine reporting ceased in April 2017

PCV2 = Pneumococcal conjugate vaccine (2 doses) (introduced Sept 2006)

PCV1= Changes to PCV schedule: All infants born on or after 1 January 2020 offered a single dose of PCV13 followed by a PCV13 booster at one year old (on or after 12 months)
This is referred to as a 1 + 1 PCV schedule. This 1 + 1 schedule will replace the previous schedule of 2 + 1 (at 8 and 16 weeks, and a booster dose given at 12 months)

**Vaccination Coverage Statistics for Children in SHSCT:
Completed Primary Immunisations by 12 months**

| Quarter* | Year | No. in cohort | Dip3 | Tet3 | Pert3 | Pol (IPV)3 | Hib3 | HepB3 | MenC | PCV2 | PCV1 | Rota2 | MenB2 |
|-----------|------|---------------|-------|-------|-------|------------|-------|-------|-------|-------|-------|-------|-------|
| Jan-Mar | 2011 | 1404 | 98.0% | 98.0% | 98.0% | 98.0% | 98.0% | | 97.9% | 98.1% | | | |
| Apr-June | 2011 | 1345 | 97.8% | 97.8% | 97.8% | 97.8% | 97.8% | | 97.6% | 97.7% | | | |
| July-Sept | 2011 | 1479 | 98.0% | 98.0% | 98.0% | 98.0% | 98.0% | | 97.7% | 97.8% | | | |
| Oct-Dec | 2011 | 1440 | 98.5% | 98.5% | 98.5% | 98.5% | 98.5% | | 98.4% | 98.3% | | | |
| Jan-Mar | 2012 | 1373 | 97.9% | 97.9% | 97.9% | 97.9% | 97.9% | | 97.7% | 97.7% | | | |
| Apr-June | 2012 | 1282 | 98.1% | 98.1% | 98.1% | 98.1% | 98.1% | | 98.0% | 98.4% | | | |
| July-Sept | 2012 | 1440 | 98.1% | 98.1% | 98.1% | 98.1% | 98.1% | | 98.1% | 98.2% | | | |
| Oct-Dec | 2012 | 1371 | 98.0% | 98.0% | 98.0% | 98.0% | 98.0% | | 97.8% | 97.8% | | | |
| Jan-Mar | 2013 | 1344 | 98.6% | 98.6% | 98.6% | 98.6% | 98.6% | | 98.6% | 98.6% | | | |
| Apr-June | 2013 | 1412 | 98.5% | 98.5% | 98.5% | 98.5% | 98.5% | | 98.6% | 98.5% | | | |
| July-Sept | 2013 | 1520 | 98.6% | 98.6% | 98.6% | 98.6% | 98.6% | | 98.0% | 98.4% | | | |
| Oct-Dec | 2013 | 1411 | 98.2% | 98.2% | 98.2% | 98.2% | 98.2% | | 96.0% | 98.0% | | | |
| Jan-Mar | 2014 | 1297 | 98.5% | 98.5% | 98.5% | 98.5% | 98.5% | | **n/a | 98.2% | | | |
| Apr-June | 2014 | 1322 | 98.4% | 98.4% | 98.4% | 98.4% | 98.4% | | **n/a | 98.3% | | | |
| July-Sept | 2014 | 1411 | 98.4% | 98.4% | 98.4% | 98.4% | 98.4% | | 98.7% | 98.4% | | 95.6% | |
| Oct-Dec | 2014 | 1356 | 99.0% | 99.0% | 99.0% | 99.0% | 99.0% | | 99.4% | 99.0% | | 96.3% | |
| Jan-Mar | 2015 | 1341 | 98.4% | 98.4% | 98.4% | 98.4% | 98.4% | | 99.0% | 98.2% | | 96.2% | |
| Apr-June | 2015 | 1367 | 98.4% | 98.4% | 98.4% | 98.4% | 98.4% | | 98.5% | 98.0% | | 95.2% | |
| July-Sept | 2015 | 1407 | 98.5% | 98.5% | 98.5% | 98.5% | 98.5% | | 98.8% | 98.4% | | 95.0% | |
| Oct-Dec | 2015 | 1394 | 97.8% | 97.8% | 97.8% | 97.8% | 97.8% | | 98.5% | 97.9% | | 95.1% | |
| Jan-Mar | 2016 | 1306 | 97.8% | 97.8% | 97.8% | 97.8% | 97.8% | | 99.1% | 97.7% | | 95.9% | |
| Apr-June | 2016 | 1309 | 97.4% | 97.4% | 97.4% | 97.4% | 97.4% | | 98.2% | 97.2% | | 95.3% | |
| July-Sept | 2016 | 1482 | 97.6% | 97.6% | 97.6% | 97.6% | 97.6% | | 98.0% | 97.4% | | 94.7% | 96.3% |
| Oct-Dec | 2016 | 1442 | 97.4% | 97.4% | 97.4% | 97.4% | 97.4% | | 97.4% | 97.6% | | 94.9% | 97.0% |
| Jan-Mar | 2017 | 1357 | 97.7% | 97.7% | 97.7% | 97.7% | 97.7% | | 90.9% | 97.6% | | 95.5% | 97.1% |
| Apr-June | 2017 | 1373 | 98.6% | 98.6% | 98.6% | 98.6% | 98.6% | | ~ | 98.6% | | 96.9% | 98.3% |
| July-Sept | 2017 | 1450 | 97.4% | 97.4% | 97.4% | 97.4% | 97.4% | | ~ | 97.4% | | 95.4% | 96.8% |
| Oct-Dec | 2017 | 1371 | 97.2% | 97.2% | 97.2% | 97.2% | 97.2% | | ~ | 97.5% | | 93.9% | 97.0% |
| Jan-Mar | 2018 | 1257 | 96.0% | 96.0% | 96.0% | 96.0% | 96.0% | | ~ | 96.4% | | 94.0% | 95.9% |
| Apr-June | 2018 | 1360 | 97.4% | 97.4% | 97.4% | 97.4% | 97.4% | | ~ | 97.4% | | 95.1% | 97.0% |
| July-Sept | 2018 | 1463 | 96.9% | 96.9% | 96.9% | 96.9% | 96.9% | 96.9% | ~ | 97.0% | | 94.8% | 96.9% |
| Oct-Dec | 2018 | 1306 | 96.0% | 96.0% | 96.0% | 96.0% | 96.0% | 96.0% | ~ | 96.2% | | 94.0% | 96.0% |
| Jan-Mar | 2019 | 1237 | 96.4% | 96.4% | 96.4% | 96.4% | 96.4% | 96.4% | ~ | 96.6% | | 93.9% | 96.4% |
| Apr-June | 2019 | 1324 | 95.4% | 95.4% | 95.4% | 95.4% | 95.4% | 95.4% | ~ | 95.5% | | 93.6% | 95.4% |
| July-Sept | 2019 | 1399 | 95.4% | 95.4% | 95.4% | 95.4% | 95.4% | 95.4% | ~ | 95.6% | | 92.8% | 95.4% |
| Oct-Dec | 2019 | 1341 | 96.0% | 96.0% | 96.0% | 96.0% | 96.0% | 96.0% | ~ | 96.0% | | 93.9% | 95.6% |
| Jan-Mar | 2020 | 1241 | 96.2% | 96.2% | 96.2% | 96.2% | 96.2% | 96.2% | ~ | 96.9% | | 93.9% | 96.5% |
| Apr-June | 2020 | 1276 | 96.0% | 96.0% | 96.0% | 96.0% | 96.0% | 96.0% | ~ | 96.5% | | 94.5% | 96.0% |
| July-Sept | 2020 | 1399 | 95.9% | 95.9% | 95.9% | 95.9% | 95.9% | 95.9% | ~ | 96.5% | | 93.3% | 96.5% |
| Oct-Dec | 2020 | 1317 | 96.1% | 96.1% | 96.1% | 96.1% | 96.1% | 96.1% | ~ | 95.7% | | 93.3% | 96.4% |
| Jan-Mar | 2021 | 1239 | 95.4% | 95.4% | 95.4% | 95.4% | 95.4% | 95.4% | ~ | ~ | 96.8% | 93.6% | 95.5% |
| Apr-June | 2021 | 1155 | 95.2% | 95.2% | 95.2% | 95.2% | 95.2% | 95.2% | ~ | ~ | 96.1% | 92.6% | 95.1% |
| July-Sept | 2021 | 1302 | 95.1% | 95.1% | 95.1% | 95.1% | 95.1% | 95.1% | ~ | ~ | 96.6% | 92.5% | 95.7% |
| Oct-Dec | 2021 | 1223 | 94.9% | 94.9% | 94.9% | 94.9% | 94.9% | 94.9% | ~ | ~ | 96.0% | 92.2% | 95.2% |

* children were 12 months old during the quarter

** accurate Men C coverage at 12 months not available (n/a) due to a software change

Dip3 = Diphtheria (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017

Tet3 = Tetanus (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017

Pert3 = Pertussis (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017

Pol (IPV)3 = Polio (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017

Hib3 = *Haemophilus Influenzae* type b (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017

HepB3 = Hepatitis B (DTaP/IPV/Hib/HepB3 vaccine) (3 doses) (introduced in August 2017)

MenC = Meningococcal serogroup C conjugate vaccine was removed from the routine immunisation schedule from 1st July 2016 and children born Jan to Mar 2016 but presenting for their 12 week immunisation late (after 1 July) may not have been offered the vaccine, resulting in decrease in coverage in Mar 2017
~ Meningococcal serogroup C conjugate vaccine reporting ceased in April 2017

PCV2 = Pneumococcal conjugate vaccine (2 doses) (introduced Sept 2006)

PCV1= Changes to PCV schedule: All infants born on or after 1 January 2020 offered a single dose of PCV13 followed by a PCV13 booster at one year old (on or after 12 months)
This is referred to as a 1 + 1 PCV schedule. This 1 + 1 schedule will replace the previous schedule of 2 + 1 (at 8 and 16 weeks, and a booster dose given at 12 months)

**Vaccination Coverage Statistics for Children in WHSCT:
Completed Primary Immunisations by 12 months**

| Quarter* | Year | No. in cohort | Dip3 | Tet3 | Pert3 | Pol (IPV)3 | Hib3 | HepB3 | MenC | PCV2 | PCV1 | Rota2 | MenB2 |
|-----------|------|---------------|-------|-------|-------|------------|-------|-------|-------|-------|-------|-------|-------|
| Jan-Mar | 2011 | 1056 | 98.2% | 98.2% | 98.2% | 98.2% | 98.2% | ~ | 98.1% | 98.3% | ~ | ~ | ~ |
| Apr-June | 2011 | 1027 | 98.3% | 98.3% | 98.3% | 98.3% | 98.3% | ~ | 98.2% | 98.3% | ~ | ~ | ~ |
| July-Sept | 2011 | 1076 | 99.3% | 99.3% | 99.3% | 99.3% | 99.3% | ~ | 99.3% | 99.3% | ~ | ~ | ~ |
| Oct-Dec | 2011 | 1065 | 98.4% | 98.4% | 98.4% | 98.4% | 98.4% | ~ | 98.4% | 98.3% | ~ | ~ | ~ |
| Jan-Mar | 2012 | 1055 | 98.3% | 98.3% | 98.3% | 98.3% | 98.3% | ~ | 98.3% | 98.3% | ~ | ~ | ~ |
| Apr-June | 2012 | 1051 | 98.7% | 98.7% | 98.7% | 98.7% | 98.7% | ~ | 98.7% | 98.7% | ~ | ~ | ~ |
| July-Sept | 2012 | 1083 | 98.8% | 98.8% | 98.8% | 98.8% | 98.8% | ~ | 99.0% | 98.8% | ~ | ~ | ~ |
| Oct-Dec | 2012 | 1060 | 98.6% | 98.6% | 98.6% | 98.6% | 98.6% | ~ | 98.6% | 98.6% | ~ | ~ | ~ |
| Jan-Mar | 2013 | 1021 | 98.3% | 98.3% | 98.3% | 98.3% | 98.3% | ~ | 98.1% | 98.1% | ~ | ~ | ~ |
| Apr-June | 2013 | 1030 | 98.9% | 98.9% | 98.9% | 98.9% | 98.9% | ~ | 99.0% | 98.9% | ~ | ~ | ~ |
| July-Sept | 2013 | 1019 | 98.9% | 98.9% | 98.9% | 98.9% | 98.9% | ~ | 98.7% | 98.9% | ~ | ~ | ~ |
| Oct-Dec | 2013 | 1068 | 97.9% | 97.9% | 97.9% | 97.9% | 97.9% | ~ | 94.5% | 97.9% | ~ | ~ | ~ |
| Jan-Mar | 2014 | 901 | 97.8% | 97.8% | 97.8% | 97.8% | 97.8% | ~ | **n/a | 97.8% | ~ | ~ | ~ |
| Apr-June | 2014 | 919 | 98.6% | 98.6% | 98.6% | 98.6% | 98.6% | ~ | **n/a | 98.6% | ~ | ~ | ~ |
| July-Sept | 2014 | 1064 | 98.3% | 98.3% | 98.3% | 98.3% | 98.3% | ~ | 98.7% | 98.3% | ~ | 93.6% | ~ |
| Oct-Dec | 2014 | 984 | 98.6% | 98.6% | 98.6% | 98.6% | 98.6% | ~ | 99.2% | 98.5% | ~ | 96.1% | ~ |
| Jan-Mar | 2015 | 942 | 97.9% | 97.9% | 97.9% | 97.9% | 97.9% | ~ | 98.7% | 98.1% | ~ | 94.6% | ~ |
| Apr-June | 2015 | 966 | 97.5% | 97.5% | 97.5% | 97.5% | 97.5% | ~ | 98.9% | 97.6% | ~ | 94.5% | ~ |
| July-Sept | 2015 | 1099 | 97.9% | 97.9% | 97.9% | 97.9% | 97.9% | ~ | 98.9% | 97.9% | ~ | 94.4% | ~ |
| Oct-Dec | 2015 | 1001 | 98.0% | 98.0% | 98.0% | 98.0% | 98.0% | ~ | 98.8% | 98.1% | ~ | 94.3% | ~ |
| Jan-Mar | 2016 | 908 | 98.0% | 98.0% | 98.0% | 98.0% | 98.0% | ~ | 99.1% | 98.0% | ~ | 94.1% | ~ |
| Apr-June | 2016 | 976 | 97.6% | 97.6% | 97.6% | 97.6% | 97.6% | ~ | 98.0% | 97.4% | ~ | 93.1% | ~ |
| July-Sept | 2016 | 1098 | 98.2% | 98.2% | 98.2% | 98.2% | 98.2% | ~ | 98.5% | 98.0% | ~ | 94.9% | 96.4% |
| Oct-Dec | 2016 | 1045 | 97.3% | 97.3% | 97.3% | 97.3% | 97.3% | ~ | 97.9% | 97.4% | ~ | 93.8% | 96.3% |
| Jan-Mar | 2017 | 964 | 97.3% | 97.3% | 97.3% | 97.3% | 97.3% | ~ | 92.6% | 97.8% | ~ | 95.4% | 97.3% |
| Apr-June | 2017 | 985 | 97.6% | 97.6% | 97.6% | 97.6% | 97.6% | ~ | ~ | 97.4% | ~ | 95.1% | 96.5% |
| July-Sept | 2017 | 1060 | 98.0% | 98.0% | 98.0% | 98.0% | 98.0% | ~ | ~ | 98.3% | ~ | 93.2% | 97.7% |
| Oct-Dec | 2017 | 975 | 96.7% | 96.7% | 96.7% | 96.7% | 96.7% | ~ | ~ | 97.3% | ~ | 93.2% | 97.3% |
| Jan-Mar | 2018 | 949 | 97.0% | 97.0% | 97.0% | 97.0% | 97.0% | ~ | ~ | 97.2% | ~ | 93.2% | 96.9% |
| Apr-June | 2018 | 948 | 96.6% | 96.6% | 96.6% | 96.6% | 96.6% | ~ | ~ | 96.6% | ~ | 94.1% | 96.6% |
| July-Sept | 2018 | 1005 | 94.9% | 94.9% | 94.9% | 94.9% | 94.9% | 94.9% | ~ | 95.3% | ~ | 91.6% | 95.2% |
| Oct-Dec | 2018 | 1020 | 95.4% | 95.4% | 95.4% | 95.4% | 95.4% | 95.4% | ~ | 95.9% | ~ | 93.0% | 95.9% |
| Jan-Mar | 2019 | 922 | 94.8% | 94.8% | 94.8% | 94.8% | 94.8% | 94.8% | ~ | 95.2% | ~ | 92.2% | 94.5% |
| Apr-June | 2019 | 970 | 95.9% | 95.9% | 95.9% | 95.9% | 95.9% | 95.9% | ~ | 96.1% | ~ | 90.3% | 95.7% |
| July-Sept | 2019 | 976 | 97.0% | 97.0% | 97.0% | 97.0% | 97.0% | 97.0% | ~ | 97.4% | ~ | 91.7% | 97.3% |
| Oct-Dec | 2019 | 927 | 95.8% | 95.8% | 95.8% | 95.8% | 95.8% | 95.8% | ~ | 96.5% | ~ | 90.5% | 96.0% |
| Jan-Mar | 2020 | 933 | 95.7% | 95.7% | 95.7% | 95.7% | 95.7% | 95.7% | ~ | 96.8% | ~ | 92.2% | 96.6% |
| Apr-June | 2020 | 877 | 96.4% | 96.4% | 96.4% | 96.4% | 96.4% | 96.4% | ~ | 96.9% | ~ | 90.5% | 96.8% |
| July-Sept | 2020 | 955 | 96.1% | 96.1% | 96.1% | 96.1% | 96.1% | 96.1% | ~ | 96.4% | ~ | 92.9% | 95.6% |
| Oct-Dec | 2020 | 915 | 96.1% | 96.1% | 96.1% | 96.1% | 96.1% | 96.1% | ~ | 95.7% | ~ | 92.6% | 96.4% |
| Jan-Mar | 2021 | 911 | 95.7% | 95.7% | 95.7% | 95.7% | 95.7% | 95.7% | ~ | ~ | 97.5% | 93.2% | 95.6% |
| Apr-June | 2021 | 879 | 96.1% | 96.1% | 96.1% | 96.1% | 96.1% | 96.1% | ~ | ~ | 97.3% | 92.7% | 97.0% |
| July-Sept | 2021 | 905 | 95.4% | 95.4% | 95.4% | 95.4% | 95.4% | 95.4% | ~ | ~ | 96.4% | 90.9% | 95.8% |
| Oct-Dec | 2021 | 960 | 95.0% | 95.0% | 95.0% | 95.0% | 95.0% | 95.0% | ~ | ~ | 96.0% | 91.8% | 95.0% |

* children were 12 months old during the quarter

** accurate Men C coverage at 12 months not available (n/a) due to a software change

Dip3 = Diphtheria (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017

Tet3 = Tetanus (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017

Pert3 = Pertussis (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017

Pol (IPV)3 = Polio (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017

Hib3 = *Haemophilus Influenzae* type b (DTaP/IPV/Hib3 vaccine) (3 doses) replaced with (DTaP/IPV/Hib/HepB3 vaccine) from August 2017

HepB3 = Hepatitis B (DTaP/IPV/Hib/HepB3 vaccine) (3 doses) (introduced in August 2017)

MenC = Meningococcal serogroup C conjugate vaccine was removed from the routine immunisation schedule from 1st July 2016 and children born Jan to Mar 2016

but presenting for their 12 week immunisation late (after 1 July) may not have been offered the vaccine, resulting in decrease in coverage in Mar 2017

~ Meningococcal serogroup C conjugate vaccine reporting ceased in April 2017

PCV2 = Pneumococcal conjugate vaccine (2 doses) (introduced Sept 2006)

PCV1= Changes to PCV schedule: All infants born on or after 1 January 2020 offered a single dose of PCV13 followed by a PCV13 booster at one year old (on or after the first birthday).

This is referred to as a 1 + 1 PCV schedule. This 1 + 1 schedule will replace the previous schedule of 2 + 1 (at 8 and 16 weeks, and a booster dose given at one year old (on or after the first birthday)).

Jan-Mar 2021 is the first quarter where only PCV1 coverage at 12 months has been evaluated

Rota2 = Rotavirus vaccine (2 doses given before 24 weeks of age) (introduced July 2013)

MenB2 = Meningococcal serogroup B vaccine (2 doses) (introduced Sept 2015)